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Argentine sublineage), poorly cross-neutralizes some Florida
sublineage Clade (Fc) 2 strains which have one amino acid sub-
stitution at position 144 in antigenic site A of the hemagglutinin,
e.g. A/equine/Carlow/2011 (CL11). Because of that, Japanese vac-
cine manufacturers are updating their vaccines by replacing LP93
with a Fc2 strain, i.e. A/equine/Yokohama/aq13/2011 (Y10, Fc2).
We compared the efﬁcacy of the updated vaccine with that of the
vaccine containing LP93 in horses experimentally challenged
with CL11. Ten naïve horses were randomly separated into 2
groups, Y10 and LP93 groups. The horses in each group were
vaccinated twice one month apart by intramuscular injection of
the monovalent vaccine containing inactivated Y10 or LP93 strain.
Two horses in each groupwere experimentally infectedwith 109.4
50% egg infectious dose/horse of CL11, twoweeks after the second
vaccination. The remaining three horses in each group were
experimentally infected four weeks after second vaccination. The
rectal temperatures were recorded, and nasopharyngeal swabs
were collected daily for 14 days after the challenge. The geometric
mean (GM) of the virus neutralization (VN) titer against CL11 of
the Y10 and LP93 groups on the day of challenge, i.e. Day 0, was
48.5 and 10.6, respectively. Contrarily, the GM haemagglutination
inhibition (HI) titers against CL11 of the Y10 and LP93 groups on
Day 0 were similar (i.e. 27.9 or 24.3, respectively). The mean rectal
temperatures of the LP93 group were signiﬁcantly higher than
those of the Y10 group on Days 2 to 7, except for Day 4 after
challenge. The mean duration (3.0 days) of pyrexia (38.5C) of
the LP93 group was signiﬁcantly longer than that of Y10 group
(0.4 days). The virus was isolated from the swabs collected from
all the horses, except for two horses in the Y10 group. No signif-
icant difference in the duration of virus shedding was observed
between the groups. This study demonstrated the superior efﬁ-
cacy of the Y10 vaccine in terms of mitigation of pyrexia
compared to that of the LP93 vaccine. The GM HI titres against
CL11 were similar for the two groups on Day 0 and the difference
in vaccine efﬁcacy was probably due to the approx. 4.6-fold dif-
ference in GM VN titres between the groups. Thus this study
suggests that in horses, VN tests are more likely than HI tests to
identify antigenic differences in inﬂuenza viruses which could
affect vaccine efﬁcacy.
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Every year, several Equine Inﬂuenza (EI) epizooties are reported
worldwide, which may have important welfare and/or economic
consequences. EI vaccination is one of the most efﬁcient methods
of prevention. However, not all horses develop protective im-
munity after EI immunisation, increasing the risk of infection,
virus shedding and the spread of the disease. Objectives: This
study aimed to better understand the poor response to primary EI
vaccination. Study design: The EI antibody response was
measured in 117 thoroughbred foals set in 3 different stud farms
(SF#1 to SF#3) during primary EI immunisation with a commer-
cial recombinant canarypox-based EI vaccine, following themanufacturer recommendations. The age at ﬁrst vaccination was
159.3±27.6 days (17 to 37weeks). Serawere tested by single radial
haemolysis (SRH) against the A/equine/Jouars/4/2006 EIV strain
(H3N8; Florida Clade 2) at the time of the ﬁrst vaccination (V1), 2
weeks and 3 months after the second immunisation (V2), 2 days
and 3 months after the third immunisation (V3). Results: The
short (V2+2 weeks) and mid-term (V2+3 months and V3+3
months) SRH antibody levels were statistically different between
the stud farms (p-value¼0.031, 0.027 and 0.0003, respectively). At
both time points, SRH antibody titres were positively correlated to
the age of foals at V1 (p-value¼0.003 and 0.0038, respectively).
Presence of maternal derived antibody (MDA) at V1 had no
impact on short-term antibody titres (V2+2 weeks; p-value¼0.27)
but was negatively correlated with titres after V3 (p-val-
ue¼0.0056). Given that SF#1 antibody response was below clin-
ical protective levels (i.e. 85 mm2) at all time points studied, the
annual boost immunization (V4) was brought forward by 5.4±1
months to restore protective antibody levels. The average age at
ﬁrst immunisationwas delayed by 48.7 days the following year in
SF#1, which signiﬁcantly increased SRH antibody titres (p-val-
ue¼9.9e-07). Conclusion: Independently of the presence of MDA,
the age of foals at ﬁrst immunisationwith the canarypox-based IE
vaccine plays an important role in the establishment of adequate
antibody levels. This study also highlights the beneﬁt provided by
serological surveillance in order to evaluate the protection level of
a speciﬁc population, to identify poor vaccine responder and to
implement corrective management/vaccination measures.
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Current equine inﬂuenza vaccines elicit a strong humoral immune
response against surface glycoproteins, in particular haemag-
glutinin (HA). However, the virus undergoes continuous evolution
by mutation of sequences encoding amino acids, mostly those
present in the exposed head domain of HA, which results in poor
induction of cross-reactive antibodies against non-matching
strains. In contrast, it has been reported that epitopes in the stem
region of HA are highly conserved and can be used to stimulate a
